bioAffinity Technologies regains Nasdaq compliance requirements

bioAffinity Technologies Inc. (NASDAQ: BIAF) announced it has regained compliance with Nasdaq listing requirements after receiving written confirmation from The Nasdaq Stock Market LLC.

The biotechnology company's common stock and warrants will continue trading on the Nasdaq Capital Market under symbols BIAF and BIAFW, respectively. Nasdaq confirmed in a letter dated October 14, 2025, that the company met the minimum closing bid price requirement of $1.00 per share and the minimum stockholders' equity requirement of $2.5 million.

"We are pleased to have regained full compliance with Nasdaq's listing standards," said Maria Zannes, president and chief executive officer of bioAffinity Technologies. "Maintaining our Nasdaq listing allows us to focus on advancing our CyPath Lung test for lung cancer and our broader pipeline of noninvasive diagnostics while also building shareholder value for the long term."

The company will be subject to a mandatory panel monitor for one year. During this monitoring period, failure to comply with the equity rule would not permit additional time to regain compliance, though the company could request a new hearing with the Nasdaq Listing Qualifications Hearing Panel before delisting.

bioAffinity Technologies develops early-stage cancer diagnostics, including CyPath Lung, a commercially available test for early-stage lung cancer. The test uses flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. Clinical study results showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules less than 20 millimeters.

You May Also Be Interested In